One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Geron Corporation logo
Geron Corporation GERN
$ 0.96 -3.03%
report update icon

Quarterly report 2026-Q3
added 11-04-2026

Geron Corporation Balance Sheet 2025-2008 | GERN

Brief overview of Geron Corporation's balance sheet structure

The comparison uses five available annual reports from the 2021–2025 interval.

Total assets increased by +152.4%, from $226 million to $570.5 million. A CAGR near 26% points to substantial expansion.

Liabilities grew faster than assets: +246% versus +152.4%. A substantial part of expansion was externally funded.

Equity represents 39.6% of assets versus 55.9% initially. The capital structure appears balanced.

Net debt equals roughly 0.19x of equity. This is a moderate load and leaves room for maneuver.

Cash accounts for 13.6% of assets versus 15.4% initially. The change indicates the degree of financial flexibility.

The balance sheet carries negative retained earnings of -$1.9 billion. The figure may result from accumulated losses or an active capital return policy.

Overall assessment

The balance sheet gives no single signal for Geron Corporation: some indicators are sound, while leverage or capitalization needs attention.

Annual Balance Sheet Geron Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Net Debt

43 M 40.4 M -34 M -25.7 M 15.9 M 15 M -11.1 M -10.6 M -16.3 M -12.8 M -21.2 M -42.8 M -13 M -22.1 M -16.1 M - - -

Long Term Debt

120 M 118 M 35.1 M 30.2 M 49.8 M 24 M - - - - - - - - - - - -

Long Term Debt Current

1 M 974 K 949 K 925 K 901 K 878 K 354 K - - - - - - - - - - -

Total Non Current Liabilities

233 M 225 M 38.1 M 33.9 M 54.1 M 28.8 M 2.2 M - - - - - - - - - - -

Total Current Liabilities

112 M 88.3 M 108 M 76.7 M 45.5 M 30.9 M 28.2 M 7.55 M 6.52 M 7.87 M 6.63 M 41.8 M 7.59 M 14.1 M 13.4 M 40.8 M - -

Total Liabilities

345 M 313 M 146 M 111 M 99.6 M 59.8 M 30.4 M 7.55 M 6.52 M 7.87 M 6.63 M 41.8 M 7.59 M 14.1 M 13.4 M - - -

Deferred Revenue

- - - - - - - - - - - 35 M - - - 350 K - -

Retained Earnings

-1.86 B -1.77 B -1.6 B -1.41 B -1.27 B -1.16 B -1.08 B -1.01 B -986 M -958 M -928 M -928 M -893 M -854 M -786 M -689 M - -

Total Assets

571 M 594 M 394 M 191 M 226 M 271 M 166 M 185 M 110 M 130 M 149 M 173 M 67.3 M 99.8 M 160 M 234 M - -

Cash and Cash Equivalents

77.6 M 79 M 70 M 56.8 M 34.9 M 9.92 M 13.6 M 10.6 M 16.3 M 12.8 M 21.2 M 42.8 M 13 M 22.1 M 16.1 M 46 M 34.6 M 109 M

Book Value

226 M 280 M 248 M 80 M 126 M 211 M 135 M 178 M 104 M 122 M 142 M 131 M 59.8 M 85.7 M 147 M 234 M - -

Total Shareholders Equity

226 M 280 M 248 M 80 M 126 M 211 M 135 M 178 M 104 M 122 M 142 M 131 M 59.8 M 85.7 M 147 M 193 M 173 M 168 M

All numbers in USD currency

Quarterly Balance Sheet Geron Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 1 M 1.23 M 1.44 M 1.66 M 1.86 M 119 M 2.27 M 2.46 M 2.64 M 11.2 M 3.01 M 3.18 M 3.5 M 51.4 M 3.67 M 37.8 M 45.3 M 50.2 M 4.27 M 34.7 M 34.4 M 24.2 M 4.8 M 4.92 M 24 M 24 M 2.2 M 2.2 M 2.2 M 2.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 3.19 M - -

Total Non Current Liabilities

226 M 230 M 231 M 233 M - - - 225 M - - - 38.1 M - - - 33.9 M - - - 54.1 M - - - 28.8 M 28.8 M - - 2.2 M 18.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

300 M 300 M 305 M 345 M - - - 313 M - - - 146 M - - - 111 M - - - 99.6 M - - - 59.8 M 53 M - - 30.4 M 30.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 35 M 35 M 35 M 35 M 35 M 35 M - - - - - - - - - - - -

Retained Earnings

-1.87 B -1.88 B -1.86 B -1.86 B -1.83 B -1.81 B -1.79 B -1.77 B -1.75 B -1.72 B -1.65 B -1.6 B -1.55 B -1.5 B -1.45 B -1.41 B -1.37 B -1.33 B -1.3 B -1.27 B -1.24 B -1.21 B -1.18 B -1.16 B -1.13 B -1.16 B -1.16 B -1.08 B -1.05 B -1.08 B -1.08 B -1.01 B -1.01 B -1.01 B -1.01 B -986 M -986 M -986 M -986 M -958 M -958 M -958 M -958 M -928 M -928 M -928 M -928 M -928 M -928 M -928 M -928 M -893 M -893 M -893 M -893 M -854 M -854 M -854 M -854 M -786 M -786 M -786 M -786 M

Total Assets

527 M 519 M 534 M 571 M 567 M 555 M 562 M 594 M 445 M 449 M 482 M 394 M 413 M 415 M 425 M 191 M 233 M 238 M 198 M 226 M 229 M 252 M 259 M 271 M 286 M 271 M 271 M 166 M 164 M 166 M 166 M 185 M 185 M 185 M 185 M 110 M 110 M 110 M 110 M 130 M 130 M 130 M 130 M 149 M 149 M 149 M 149 M 173 M 173 M 173 M 173 M 67.3 M 67.3 M 67.3 M 67.3 M 99.8 M 99.8 M 99.8 M 99.8 M 160 M 160 M 160 M 160 M

Cash and Cash Equivalents

71.1 M 64.5 M 68.9 M 77.6 M 80 M 79.6 M 83.7 M 79 M 60.3 M 117 M 190 M 70 M 30.7 M 56.9 M 113 M 56.8 M 61.1 M 76.1 M 31.3 M 34.9 M 29 M 57.3 M 31.5 M 9.92 M 45 M 9.92 M 9.92 M 13.6 M 20.8 M 13.6 M 13.6 M 10.6 M 10.6 M 10.6 M 10.6 M 16.6 M 16.3 M 16.3 M 16.3 M 12.8 M 12.8 M 12.8 M 12.8 M 21.2 M 21.2 M 21.2 M 21.2 M 42.8 M 42.8 M 42.8 M 42.8 M 13 M 13 M 13 M 13 M 22.1 M 22.1 M 22.1 M 22.1 M 16.1 M 16.1 M 16.1 M 16.1 M

Book Value

227 M 219 M 229 M 226 M 567 M 555 M - 280 M 445 M 449 M - 248 M 413 M 415 M - 80 M 233 M 238 M 198 M 126 M 229 M 252 M 259 M 211 M 233 M 271 M 271 M 135 M 134 M 166 M 166 M 185 M 185 M 185 M 185 M 110 M 110 M 110 M 110 M 130 M 130 M 130 M 130 M 149 M 149 M 149 M 149 M 173 M 173 M 173 M 173 M 67.3 M 67.3 M 67.3 M 67.3 M 99.8 M 99.8 M 99.8 M 99.8 M 160 M 160 M 160 M 160 M

Total Shareholders Equity

227 M 219 M 229 M 226 M 249 M 260 M 268 M 280 M 292 M 307 M 345 M 248 M 291 M 298 M 326 M 80 M 108 M 142 M 97.5 M 126 M 152 M 176 M 201 M 211 M 233 M 211 M 211 M 135 M 152 M 135 M 135 M 178 M 178 M 178 M 178 M 104 M 104 M 104 M 104 M 122 M 122 M 122 M 122 M 142 M 142 M 142 M 142 M 131 M 131 M 131 M 131 M 59.8 M 59.8 M 59.8 M 59.8 M 85.7 M 85.7 M 85.7 M 85.7 M 147 M 147 M 147 M 147 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Geron Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.47 -0.97 % $ 775 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 3.95 12.07 % $ 52.6 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.21 -11.68 % $ 55.3 M israelIsrael
AnaptysBio AnaptysBio
ANAB
$ 48.4 0.9 % $ 1.4 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 21.33 -2.11 % $ 239 M usaUSA
Adagene Adagene
ADAG
$ 2.02 -4.95 % $ 119 M chinaChina
Benitec Biopharma Benitec Biopharma
BNTC
$ 9.31 -5.67 % $ 433 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 19.85 -2.36 % $ 3.43 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.75 0.09 % $ 4.88 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 10.4 1.76 % $ 93.9 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.5 -9.09 % $ 222 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 31.77 1.23 % $ 1.84 B usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 18.89 -6.21 % $ 1.79 B usaUSA
Equillium Equillium
EQ
$ 1.45 -3.33 % $ 83.1 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.6 -14.05 % $ 91 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 2.46 -3.35 % $ 130 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 18.13 9.85 % $ 3.05 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 2.21 3.76 % $ 19 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.51 -9.88 % $ 192 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 33.57 -0.62 % $ 1.93 B usaUSA
Ardelyx Ardelyx
ARDX
$ 3.0 2.39 % $ 723 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.54 1.8 % $ 139 M usaUSA
Alector Alector
ALEC
$ 2.54 3.05 % $ 262 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.11 -13.62 % $ 59.6 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 21.39 0.52 % $ 6.7 B usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 5.45 2.16 % $ 397 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 3.8 2.15 % $ 728 M canadaCanada
Agenus Agenus
AGEN
$ 7.02 -1.82 % $ 209 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.44 -0.52 % $ 3.72 B canadaCanada
Artelo Biosciences Artelo Biosciences
ARTL
$ 2.14 2.01 % $ 405 K usaUSA
Immatics N.V. Immatics N.V.
IMTX
$ 6.42 -0.23 % $ 785 M germanyGermany
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.08 -4.42 % $ 341 K usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 2.59 -34.43 % $ 25.6 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 4.13 -2.5 % $ 506 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 29.38 -2.91 % $ 4.46 B usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.24 -3.15 % $ 3.23 M usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
$ 2.68 5.93 % $ 223 M usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 0.78 -2.19 % $ 47.9 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 13.02 -1.06 % $ 8.97 B niderlandNiderland
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 8.91 -9.54 % $ 414 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 29.06 -1.09 % $ 1.36 B usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 3.52 -0.56 % $ 376 M usaUSA
Jaguar Health Jaguar Health
JAGX
$ 0.44 -0.21 % $ 1.03 M usaUSA
Arvinas Arvinas
ARVN
$ 6.9 2.07 % $ 489 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.95 -6.04 % $ 372 M usaUSA